NCT07185113View on ClinicalTrials.gov

A Study to Assess the Pharmacokinetics of GEn-1124 After Single Oral Dosing in Healthy Subjects

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Healthy Adult Male
Interventions
DRUG

GEn-1124

GEn-1124 will be administered to one single dose group of subjects dosed under fed (standardized meal) conditions. GEn-1124 will be administered as an oral capsule formulation containing GEn-1124.

Trial Locations (1)

8011

New Zealand Clinical Research (NZCR), Christchurch

Sponsors

Lead Sponsor

GEn1E Lifesciences
All Listed Sponsors
collaborator

InClin, Inc.

UNKNOWN

lead

GEn1E Lifesciences

INDUSTRY